<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title> &#187; FDA</title>
	<atom:link href="http://pharmaexecnews.com/category/fda/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmaexecnews.com</link>
	<description></description>
	<lastBuildDate>Fri, 29 Apr 2011 14:00:12 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Preventing Damage from Heart Attacks &amp; Strokes with an Injection</title>
		<link>http://pharmaexecnews.com/biotechnology/preventing-damage-heart-attacks-strokes-injection/</link>
		<comments>http://pharmaexecnews.com/biotechnology/preventing-damage-heart-attacks-strokes-injection/#comments</comments>
		<pubDate>Tue, 26 Apr 2011 08:00:42 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Cardiovascular]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[New Drugs]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11510</guid>
		<description><![CDATA[A researching team from the University of Leicester has offered the promise of a simple injection that could be developed to restrict the damage that results from heart attacks and strokes. Described by the lead researcher as &#8216;a fascinating new achievement&#8217;, work has already begun to translate the research into novel clinical therapies.

Professor Wilhelm Schwaeble [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/preventing-damage-heart-attacks-strokes-injection/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nasal Spray Vaccines More Effective against Flu</title>
		<link>http://pharmaexecnews.com/biotechnology/nasal-spray-vaccines-effective-flu/</link>
		<comments>http://pharmaexecnews.com/biotechnology/nasal-spray-vaccines-effective-flu/#comments</comments>
		<pubDate>Thu, 21 Apr 2011 08:00:14 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11485</guid>
		<description><![CDATA[New research has shown that nasal vaccines are much more effective in providing protection against the flu. In fact the research also proved that nasal vaccines will soon protect not only against the flu and pneumonia, but also against bioterrorism agents such as Yersinia pestis that causes the plague. The research, presented at the Society [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/nasal-spray-vaccines-effective-flu/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Drug Shows Unprecedented Weight Loss in Clinical Trials</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/drug-shows-unprecedented-weight-loss-clinical-trials/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/drug-shows-unprecedented-weight-loss-clinical-trials/#comments</comments>
		<pubDate>Wed, 20 Apr 2011 14:00:20 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drug Trials]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11497</guid>
		<description><![CDATA[An investigational combination of drugs already approved to treat obesity, migraine and epilepsy produced up to a 10 percent weight loss in obese individuals participating in a one-year clinical trial, according to researchers at Duke University  Medical Center.

The study has found that treatment with the controlled-release combination therapy made up of phentermine and topiramate [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/drug-shows-unprecedented-weight-loss-clinical-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis Completes $125M Acquisition of Tianyuan</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/companies/novartis-completes-125m-acquisition-tianyuan/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/companies/novartis-completes-125m-acquisition-tianyuan/#comments</comments>
		<pubDate>Fri, 25 Mar 2011 14:00:27 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Companies]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11369</guid>
		<description><![CDATA[Novartis has completed its acquisition of 85% in the Chinese vaccines firm Zhejiang Tianyuan Bio-Pharmaceutical. The deal, roughly valued at $125 million, was first announced in November 2009. Swiss drugs giant Novartis has said that the acquisition will provide it with an expanded presence in the Chinese vaccines market and also facilitate the introduction of [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/companies/novartis-completes-125m-acquisition-tianyuan/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Warns of Drug Scams that Play on Radiation Fear</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/fda-warns-drug-scams-play-radiation-fear/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/fda-warns-drug-scams-play-radiation-fear/#comments</comments>
		<pubDate>Mon, 21 Mar 2011 08:00:13 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[FDA]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11338</guid>
		<description><![CDATA[Many of the ads for &#8220;anti-radiation&#8221; potassium iodide pills flooding the Internet may be scams run by hucksters seeking to profit from the Japan nuclear scare, the Food and Drug Administration warned Thursday.  &#8220;We found many different offers for potassium iodide and other products that we&#8217;re taking a look at,&#8221; says Gary Coody, the FDA&#8217;s [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/fda-warns-drug-scams-play-radiation-fear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Now – Nanoparticles for Long Lasting Immunity</title>
		<link>http://pharmaexecnews.com/biotechnology/nanoparticles-long-lasting-immunity/</link>
		<comments>http://pharmaexecnews.com/biotechnology/nanoparticles-long-lasting-immunity/#comments</comments>
		<pubDate>Tue, 15 Mar 2011 08:00:07 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Nanotechnology]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[nano]]></category>
		<category><![CDATA[nanobiotechnology]]></category>
		<category><![CDATA[nanotechnology]]></category>
		<category><![CDATA[Nanotechnology - Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11290</guid>
		<description><![CDATA[Every vaccine scientist wants to discover just one thing – how to stimulate immunity that lasts for a lifetime! There are many live vaccines, such as the ones for smallpox and yellow fever that are able to stimulate immunity against the disease that lasts for many decades. However, in spite of the success of such [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/nanoparticles-long-lasting-immunity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Generic Fees Gain Traction with FDA Backing</title>
		<link>http://pharmaexecnews.com/biotechnology/generic-fees-gain-traction-fda-backing/</link>
		<comments>http://pharmaexecnews.com/biotechnology/generic-fees-gain-traction-fda-backing/#comments</comments>
		<pubDate>Fri, 04 Mar 2011 14:00:10 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Generics]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11246</guid>
		<description><![CDATA[It looks as if user fees really are in the offing for generic drugs. After generics makers said last week that they&#8217;re supporting the idea as a way to speed approvals of their products, FDA Commissioner Margaret Hamburg backed it, too. Revamping the current approvals process is &#8220;critical,&#8221; she said, because agency funding won&#8217;t provide [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/generic-fees-gain-traction-fda-backing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>OTC Allegra Nod Fortifies Sanofi&#8217;s U.S. Consumer Ops</title>
		<link>http://pharmaexecnews.com/pharmaceuticals/otc-allegra-nod-fortifies-sanofis-consumer-ops/</link>
		<comments>http://pharmaexecnews.com/pharmaceuticals/otc-allegra-nod-fortifies-sanofis-consumer-ops/#comments</comments>
		<pubDate>Fri, 25 Feb 2011 14:00:39 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Companies]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11219</guid>
		<description><![CDATA[Sanofi-Aventis continues its diversification march. The company got the FDA&#8217;s permission to sell its blockbuster allergy treatment Allegra without a prescription. Sanofi has been hoping for that OK to bolster its U.S. consumer healthcare business that was created last year with the $1.9 billion purchase of Chattem.

At the time, both companies trumpeted OTC Allegra&#8217;s potential [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/pharmaceuticals/otc-allegra-nod-fortifies-sanofis-consumer-ops/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Inhalable Measles Vaccine Tested</title>
		<link>http://pharmaexecnews.com/biotechnology/inhalable-measles-vaccine-tested/</link>
		<comments>http://pharmaexecnews.com/biotechnology/inhalable-measles-vaccine-tested/#comments</comments>
		<pubDate>Fri, 25 Feb 2011 08:00:43 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11197</guid>
		<description><![CDATA[Sustained high vaccination coverage is key to preventing deaths from measles. Despite the availability of a vaccine, measles remains an important killer of children worldwide, particularly in less-developed regions where vaccination coverage is limited. A team of researchers, led by scientists at the Johns Hopkins Bloomberg School of Public Health and the University of Colorado, [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/inhalable-measles-vaccine-tested/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rate of Drug Approvals Dropping</title>
		<link>http://pharmaexecnews.com/biotechnology/rate-drug-approvals-dropping/</link>
		<comments>http://pharmaexecnews.com/biotechnology/rate-drug-approvals-dropping/#comments</comments>
		<pubDate>Thu, 17 Feb 2011 08:00:22 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Drug Trials]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=11173</guid>
		<description><![CDATA[Want proof that achieving FDA approval is more difficult than in the past? A study released by the BIO and BioMedTracker that the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is near one in 10. Previously the rate of approval were one [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/rate-drug-approvals-dropping/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

